A single-center retrospective cohort study published in Pulmonology evaluated the clinical and economic burden of respiratory syncytial virus-associated acute respiratory infection (RSV-ARI) among adults hospitalized over six consecutive respiratory seasons (2018/19–2023/24), including the COVID-19 disruption period. Among 7,125 acute respiratory infection hospitalizations, 3,011 patients underwent RSV and influenza testing. The prevalence of RT-PCR-confirmed RSV-ARI was 8.1%, and the study included 244 RSV-ARI admissions.
Most patients were ≥60 years, and 77.1% had high-risk comorbidities. Complications within 90 days were common, including acute cardiac events (47.1%), respiratory failure (46.3%), pneumonia (34.0%), and acute renal disease (34.0%). The all-cause in-hospital mortality rate was 19.7%, with a mean hospital stay of 8.5 days and an average direct hospitalization cost of…
